Drugs / LNF2105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07661797 | Jun 2026 → Jun 2028 expected | — | Shandong New Time Pharmaceutical Co., LTD | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LNF2105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07661797 ↗ |